A study from Watson School of Biological Sciences shows that Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling. This study was published in the April 10, 2014 Cell by Prof. Dr Scott Lowe, Watson School of Biological Sciences, CSHL, New York; Prof. Dr Carol Prives, Department of Biological Sciences, Columbia University, New York; and others.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Tumor suppressor p33(ING1b) suppresses the expression of PDGF Receptor β (PDGFRβ) via up regulation of its target gene. This study suggests that ING1b, by suppressing the expression of its target gene PDGF Receptor β, it could inhibit the invasion of mutant p53 expressing human cancers. Given that tumor suppressor p53 is mutated in about 50% of different human cancers, this study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human cancers can be cured. Together, this study suggests that pharmacological formulations encompassing “ING1b activators” can be used to treat Metastatic Pancreatic/intestine/ovarian Cancer.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Tumor suppressor p33(ING1b) suppresses the expression of PDGF Receptor β (PDGFRβ) via up regulation of its target gene, 18/July/2014, 5.14 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation